AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Sofosbuvir and 007 pharmacokinetics among persons with HCV and active drug useView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Tenofovir plasma concentrations in pregnant women: comparison of hepatitis B and HIV-infected patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019HBV infections among HIV-infected mothers on ART and their exposed infants in a tertiary hospital, Nairobi KenyaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Model-based simulted 3TC exposure in HIV population by varying renal functionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019PBPK modelling and simulation of ritonavir-boosted atazanavir (ATV/r) dosing when co-administered with rifampicin (RIF)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Alteration of hepatic OATP activity does not alter the pharmacodynamic effect of GS-0976, a liver targeted ACC inhibitor, on de novo lipogenesisView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacokinetic (PK) and pharmacocokinetic/pharmacodynamic characterization of the two-drug anti-retroviral regimen (2DR) dolutegravir/rilpivirine following switch from current anti-retroviral therapy in the SWORD-1 and SWORD-2 Phase 3 studiesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Characterization of binding of dolutegravir to plasma proteinsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Antiretroviral penetration and drug transporter concentrations in the spleens of three preclinical animal models and humansView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at a referral hospital in EthiopiaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Temsavir concentration (Cp)-QTc relationship following administration of fostemsavirView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Plasma and intracellular pharmacokinetics of cobicistat in the clinical settingView Abstract
